Second- and Third-generation Aromatase Inhibitors as First-line Endocrine Therapy in Postmenopausal Metastatic Breast Cancer Patients: A Pooled Analysis of the Randomised Trials

Cancer Patients ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Pooled Analysis ◽

Third Generation ◽

Breast Cancer Patients ◽

Randomised Trials ◽

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

British Journal of Cancer ◽

10.1038/sj.bjc.6603194 ◽

2006 ◽

Vol 94 (12) ◽

pp. 1789-1796 ◽

Cited By ~ 23

Author(s):

G Ferretti ◽

E Bria ◽

D Giannarelli ◽

A Felici ◽

P Papaldo ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Pooled Analysis ◽

Third Generation ◽

Breast Cancer Patients ◽

Randomised Trials ◽

Faculty of 1000 evaluation for Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.723662248.793506856 ◽

2015 ◽

Author(s):

Kent Hunter

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Pooled Analysis ◽

Third Generation ◽

Breast Cancer Patients ◽

Randomised Trials ◽

Efficacy of First Line Regimens in Metastatic Breast Cancer Patients. Real World Evidence from Instituto Nacional de Cancerologia, Mexico City

The Breast ◽

10.1016/s0960-9776(17)30699-9 ◽

2017 ◽

Vol 36 ◽

pp. S50

Author(s):

Maria Tereza Nieto-Coronel ◽

Claudia Arce Salinas ◽

Ariana Tabares ◽

Jose Luis Aguilar-Ponce

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Mexico City ◽

Real World ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Real World Evidence

375 Effect of adjuvant chemotherapy (ACT) with or without anthracyclines on first line CEF in metastatic breast cancer patients (PTS)

European Journal of Cancer ◽

10.1016/0959-8049(95)95628-j ◽

1995 ◽

Vol 31 ◽

pp. S82

Author(s):

M. Venturini ◽

L. Del Mastro ◽

P. Bruzzi ◽

O. Garrone ◽

M.R. Sertoli ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603351 ◽

2006 ◽

Vol 95 (7) ◽

pp. 788-793 ◽

Cited By ~ 43

Author(s):

A Chan ◽

◽

M Martin ◽

M Untch ◽

M G Gil ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Her 2

Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors

European Geriatric Medicine ◽

10.1016/j.eurger.2017.06.004 ◽

2017 ◽

Vol 8 (5-6) ◽

pp. 408-412

Author(s):

V. Gunmalm ◽

N.R. Jørgensen ◽

B. Abrahamsen ◽

P. Schwarz

Keyword(s):

Breast Cancer ◽

Bone Loss ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Prevention Of Bone Loss

S3-3: Association of PTEN Loss and PIK3CA Mutations on Outcome in HER2+ Metastatic Breast Cancer Patients Treated with First-Line Lapatinib Plus Paclitaxel or Paclitaxel Alone.

10.1158/0008-5472.sabcs11-s3-3 ◽

2011 ◽

Cited By ~ 1

Author(s):

B Xu ◽

Z-Z Guan ◽

Z-Z Shen ◽

Z-S Tong ◽

Z-F Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Pik3ca Mutations ◽

Pten Loss

Abstract P2-13-03: Prevalence of non-metastatic breast cancer patients treated with aromatase inhibitors in the United States

10.1158/0008-5472.sabcs12-p2-13-03 ◽

2012 ◽

Cited By ~ 1

Author(s):

A Liede ◽

RK Hernandez ◽

M Pirolli ◽

J Quigley ◽

D Quach

Keyword(s):

Breast Cancer ◽

United States ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

The United States ◽

Breast Cancer Patients

Abstract P1-01-02: Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

10.1158/1538-7445.sabcs16-p1-01-02 ◽

2017 ◽

Author(s):

J-Y Pierga ◽

O Tredant ◽

M Chevrier ◽

C Dubot ◽

V Lorgis ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Cancer Patients ◽

Tumor Cells ◽

Prognostic Value ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

First Results

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab

The Breast ◽

10.1016/j.breast.2015.09.008 ◽

2015 ◽

Vol 24 (6) ◽

pp. 751-757 ◽

Cited By ~ 15

Author(s):

B. Yeo ◽

K. Kotsori ◽

K. Mohammed ◽

G. Walsh ◽

I.E. Smith

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

First Line ◽

Her2 Positive ◽

Term Outcome ◽

Long Term Outcome